06.02.2018 13:19:07
|
Bio-Techne Q2 Profit Beats Estimates; Organic Revenue Up 14% - Quick Facts
(RTTNews) - Bio-Techne Corp. (TECH) reported that its second-quarter adjusted EPS increased to $1.02, from $0.81 in the same quarter last year. Adjusted operating income increased 16% from prior year. On average, nine analysts polled by Thomson Reuters expected the company to report profit per share of $0.92 for the quarter. Analysts' estimates typically exclude special items.
Second-quarter net sales increased 17% to $154.2 million. Organic growth was 14% compared to the prior year, with currency translation having a positive impact of 2% and acquisitions contributing 1% to revenue growth. Analysts expected revenue of $146.29 million for the quarter.
"Our company had extraordinary performance in the second quarter on both the top and bottom-line. These were the best results since we started to transform the company nearly five years ago. The investments made in the core company and the synergies with our strategic acquisitions are beginning to display nice leverage and upside," said Chuck Kummeth, CEO of Bio-Techne.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bio-Techne Corpmehr Nachrichten
13.02.25 |
S&P 500-Papier Bio-Techne-Aktie: Wäre eine Bio-Techne-Kapitalanlage von vor einem Jahr lukrativ gewesen? (finanzen.at) | |
10.02.25 |
Börse New York: S&P 500 liegt schlussendlich im Plus (finanzen.at) | |
10.02.25 |
Starker Wochentag in New York: S&P 500 verbucht Gewinne (finanzen.at) | |
10.02.25 |
Aufschläge in New York: Börsianer lassen S&P 500 am Montagmittag steigen (finanzen.at) | |
10.02.25 |
Handel in New York: S&P 500 bewegt sich zum Start im Plus (finanzen.at) | |
06.02.25 |
S&P 500-Titel Bio-Techne-Aktie: So viel Gewinn hätte ein Bio-Techne-Investment von vor 10 Jahren eingefahren (finanzen.at) | |
05.02.25 |
Verluste in New York: S&P 500 zum Handelsstart in Rot (finanzen.at) | |
04.02.25 |
Ausblick: Bio-Techne vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu Bio-Techne Corpmehr Analysen
Aktien in diesem Artikel
Bio-Techne Corp | 63,50 | 0,00% |
|